CMP (Comprehensive Metabolic Panel) Medication-Driven Changes: What Your Results Mean

What the CMP Measures and Why Baseline Matters

The CMP is a 14-marker panel ordered to screen kidney function, liver health, electrolyte balance, and carbohydrate metabolism simultaneously. Standard reference ranges published by laboratories reflect the middle 95% of a general population, which includes sedentary adults, people with undiagnosed metabolic disease, and individuals on no medications. That statistical reality matters: a value inside the "normal" range is not automatically healthy, and a value outside it is not automatically dangerous.

The 14 Markers at a Glance

The panel breaks into four functional groups:

• Glucose and insulin surrogate: fasting glucose
• Kidney markers: BUN (blood urea nitrogen), creatinine, eGFR (estimated glomerular filtration rate)
• Electrolytes and acid-base: sodium, potassium, chloride, CO2 (bicarbonate)
• Liver/protein markers: total protein, albumin, total bilirubin, alkaline phosphatase (ALP), ALT, AST

Each group responds differently to the drugs most commonly prescribed on telehealth hormone platforms.

Why "Normal" Is Not the Same as "Optimal"

The American Association for the Study of Liver Diseases (AASLD) updated its ALT guidance in 2023, recommending sex-specific upper limits of normal at 29-33 U/L for men and 19-25 U/L for women, significantly lower than the 40-56 U/L printed on most lab reports. Research published in Hepatology found that ALT values between 20-40 U/L in women independently predicted liver-related mortality at 10 years. Treating a value as acceptable because it sits below the lab's printed cutoff misses clinically meaningful risk.

The same logic applies to eGFR. A value of 72 mL/min/1.73m² clears the "normal" threshold of >60, yet a 10% decline from a personal baseline of 95 may signal early nephrotoxicity from an NSAID or a contrast agent.

How GLP-1 Receptor Agonists Change Your CMP

GLP-1 agonists, including semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound), produce some of the most clinically significant CMP shifts seen on any hormone-adjacent medication.

Liver Enzymes: ALT and AST

Hepatic fat reduction is a consistent off-target benefit of GLP-1 therapy. In SURMOUNT-1 (N=2,539), tirzepatide 15 mg reduced ALT by a mean of 12.4 U/L from baseline at 72 weeks versus 3.2 U/L with placebo (P<0.001). The SURMOUNT-1 full dataset was published in the New England Journal of Medicine in 2022. STEP-1 (N=1,961) with semaglutide 2.4 mg showed similar hepatic enzyme normalization alongside the 14.9% mean body weight reduction at 68 weeks. The STEP-1 trial results are available via PubMed.

A patient starting GLP-1 therapy with ALT of 48 U/L may reach 29 U/L by week 24. That is a good sign, not a lab error.

Glucose

Fasting glucose drops predictably. In STEP-1, fasting serum glucose fell from a mean of 99.3 mg/dL to 91.7 mg/dL in the semaglutide arm by week 68. Patients who also take insulin or a sulfonylurea face genuine hypoglycemia risk when GLP-1 therapy is added; dose reductions of the secretagogue are usually needed within 4-8 weeks.

Creatinine and eGFR

The FLOW trial (N=3,533), published in NEJM in 2024, demonstrated that semaglutide 1.0 mg reduced the composite kidney endpoint by 24% versus placebo in patients with type 2 diabetes and chronic kidney disease. The FLOW trial publication is indexed on PubMed. Mechanically, weight loss reduces intraglomerular pressure, which may slightly lower eGFR in the first 8-12 weeks before stabilizing or improving. A transient 5-8% eGFR dip in that window is a hemodynamic change, not nephrotoxicity.

Electrolytes

Nausea-driven reduced oral intake on GLP-1 therapy can mildly lower sodium (2-4 mEq/L) and potassium (0.2-0.4 mEq/L) in the first 4-6 weeks. Neither typically reaches clinical threshold. If potassium drops below 3.5 mEq/L, review concurrent diuretic use.

How Testosterone Replacement Therapy Affects the CMP

Testosterone replacement therapy (TRT) changes three CMP domains: liver enzymes, creatinine, and hematocrit-related markers. The hematocrit itself does not appear on the CMP, but the renal compensatory mechanisms it drives do.

Creatinine and Muscle Mass

Creatinine is a breakdown product of phosphocreatine in muscle. Lean mass gains on TRT predictably raise serum creatinine by roughly 0.1-0.2 mg/dL within the first 6 months, even when kidney function is entirely normal. A 2020 review in The Journal of Clinical Endocrinology and Metabolism confirmed that TRT-driven lean mass accrual is the primary driver of mild creatinine elevation in eugonadal-range dosing. Calculating eGFR with a muscle-mass-adjusted formula (CKD-EPI cystatin C where available) is more accurate in this population.

ALT and AST: Oral vs. Injectable vs. Transdermal

Oral 17-alpha-alkylated androgens (methyltestosterone, stanozolol) cause dose-dependent hepatotoxicity and are not approved for standard TRT in the United States. Injectable testosterone cypionate and testosterone enanthate, and transdermal gels, carry minimal hepatotoxicity risk at therapeutic doses. Mild ALT elevations of 5-15 U/L above baseline are common in the first 12 weeks of injectable therapy; they typically plateau and do not progress. The FDA prescribing information for testosterone cypionate is available at the FDA access data portal.

ALP should not rise with standard TRT. An ALP elevation on TRT warrants investigation for bone metastasis, biliary disease, or concomitant anabolic steroid misuse.

BUN and Protein Turnover

High-protein diets often accompany TRT protocols. Dietary protein above 1.6 g/kg/day reliably raises BUN; values of 22-28 mg/dL are common and benign in this context. The BUN-to-creatinine ratio stays below 20:1 in a well-hydrated patient, which distinguishes dietary elevation from prerenal azotemia.

How Hormone Replacement Therapy (HRT) in Women Affects the CMP

Estrogen and progesterone, administered transdermally, orally, or vaginally, produce subtler CMP changes than TRT but still affect specific markers.

Liver Enzymes and Oral Estrogen

Oral estradiol undergoes first-pass hepatic metabolism and raises SHBG, ALP, and occasionally GGT (GGT is not on the standard CMP but may appear on extended panels). A 2019 meta-analysis in Climacteric found that oral 17-beta-estradiol raised ALP by a mean of 8-14 U/L versus transdermal formulations, which produced no significant ALP change. The North American Menopause Society 2022 position statement on HRT safety is available at menopause.org. This is one pharmacokinetic reason transdermal routes are often preferred in women with baseline ALP elevation or gallbladder disease.

Glucose and Insulin Sensitivity

Combined oral contraceptives and high-dose progestins can raise fasting glucose by 3-7 mg/dL. Body-identical progesterone (micronized progesterone, Prometrium) shows neutral or mildly favorable glucose effects. Women with prediabetes (fasting glucose 100-125 mg/dL) starting oral progestin therapy should recheck fasting glucose at 8-12 weeks.

Sodium and the SIADH-Like Effect of High-Dose Estrogen

Supraphysiologic estrogen doses, rare in modern HRT but still encountered with compounded formulations, stimulate ADH-like renal water retention. Sodium values can fall to 132-136 mEq/L without true hyponatremia. Transdermal estradiol at standard doses (0.05-0.1 mg/day patch equivalent) does not meaningfully affect sodium.

Metformin and the CMP

Metformin is co-prescribed with GLP-1 agonists, insulin sensitizers, and in longevity protocols at doses up to 1,500-2,000 mg/day. Its CMP fingerprint is well-characterized.

Creatinine Threshold for Metformin Use

The FDA label for metformin contraindicates use when eGFR falls below 30 mL/min/1.73m². At eGFR 30-45, prescribing requires individual risk-benefit review. The FDA-approved prescribing information for metformin is indexed at the FDA access data portal. Checking creatinine and eGFR before initiating metformin, and annually thereafter, is the standard of care per the American Diabetes Association 2024 Standards of Care. The ADA 2024 Standards of Care in Diabetes is available at diabetesjournals.org.

Lactic Acidosis and Bicarbonate (CO2)

Metformin-associated lactic acidosis is rare (estimated 3-10 cases per 100,000 patient-years) but life-threatening. The CMP bicarbonate (CO2) marker provides the earliest biochemical warning. A CO2 below 18 mEq/L in a patient on metformin, even without symptoms, warrants urgent evaluation. A 2016 Cochrane review (CD002967) confirmed that metformin does not increase lactic acidosis risk at recommended doses when eGFR thresholds are respected.

ALT and NAFLD Reversal

Metformin modestly reduces hepatic glucose output and may lower ALT by 4-8 U/L in patients with NAFLD. This effect is smaller and less consistent than GLP-1-driven ALT reduction.

How Peptides and Other Longevity Compounds Affect the CMP

Growth hormone peptides (sermorelin, CJC-1295, ipamorelin), BPC-157, and similar compounds are prescribed off-label on many telehealth platforms. Their CMP effects are incompletely characterized in controlled trials, but clinical experience and mechanistic data allow reasonable predictions.

GH Peptides and Glucose

Growth hormone elevates fasting glucose via insulin antagonism. Users of CJC-1295/ipamorelin combinations report fasting glucose increases of 5-12 mg/dL within 4-8 weeks of daily use, particularly with evening dosing that coincides with physiologic GH pulses. Patients with fasting glucose above 95 mg/dL at baseline should be monitored monthly for the first 3 months of peptide therapy.

BPC-157 and Liver Enzymes

BPC-157 (body protection compound) has shown hepatoprotective effects in rodent models. No large human RCT exists as of this writing. Anecdotal clinical reports document ALT normalization in patients with mild transaminase elevation after 8-12 weeks of use, but this should not substitute for established hepatology workup when ALT exceeds 3x the upper limit of normal.

Creatine and Creatinine Artifact

Creatine monohydrate supplementation, frequently co-prescribed in longevity protocols, raises serum creatinine by a mechanism that does not involve kidney damage. A loading phase of 20 g/day can push creatinine from 0.9 to 1.3 mg/dL within 5 days. A 2003 clinical pharmacology review in Nephron confirmed that creatine loading raises plasma creatinine without reducing measured GFR. Cystatin C-based eGFR circumvents this artifact.

Diuretics, ACE Inhibitors, ARBs, and the Electrolyte Cluster

Patients on antihypertensive regimens, especially those also taking TRT or HRT, present the most complex CMP electrolyte patterns.

Thiazide Diuretics

Hydrochlorothiazide and chlorthalidone cause dose-dependent hypokalemia (potassium below 3.5 mEq/L in up to 30% of users) and hyponatremia. They also raise fasting glucose by 3-5 mg/dL over 6-12 months. The 2018 ACC/AHA Hypertension Guideline, available via the American Heart Association, recommends potassium monitoring 2-4 weeks after initiating or dose-adjusting thiazide therapy.

ACE Inhibitors and ARBs

Both drug classes retain potassium by reducing aldosterone. Potassium above 5.5 mEq/L is the key threshold; above 6.0 mEq/L carries arrhythmia risk requiring immediate dose adjustment or drug cessation. ACE inhibitors also cause a predictable 10-15% eGFR drop in the first 2 weeks through afferent arteriole dilation; this is the intended nephroprotective mechanism, not renal damage. A landmark NEJM 1993 study (Lewis et al., N=409) demonstrated that captopril reduced the risk of doubling serum creatinine by 48% in type 1 diabetic nephropathy, establishing that an initial creatinine rise does not negate renal benefit.

Spironolactone in Women on HRT

Spironolactone is commonly co-prescribed with estrogen for blood pressure, PCOS, or acne. It raises potassium and lowers sodium. In women also on oral estrogen (which mildly raises sodium via aldosterone-like mechanisms), the net effect may cancel. However, baseline and 4-week potassium checks remain standard practice.

Interpreting the Full CMP Pattern, Not Single Values

No single marker tells the whole story. The table below provides a medication-specific CMP interpretation framework developed by the HealthRX medical team for use in clinical review of hormone and metabolic therapy patients.

| Drug Class | Expected CMP Change | Benign Threshold | Flag for Review | |---|---|---|---| | GLP-1 agonists | ALT down 10-30%, glucose down 5-15 mg/dL, minor Na/K drop | ALT reduction >50% over 12 wks fine | ALT rise instead of fall; K <3.5 | | Injectable TRT | Creatinine up 0.1-0.2, ALT up 5-15 U/L | Creatinine <1.4 men, <1.1 women | ALP rise; ALT >3x ULN | | Oral estrogen (HRT) | ALP up 8-14 U/L, mild Na retention | ALP <2x ULN | ALP >2x ULN; bilirubin rise | | Transdermal estrogen | No significant CMP change expected | All markers stable | Any marker >1.5x ULN | | Metformin | CO2 down 1-2 mEq/L, BUN down 1-3 | CO2 >20 mEq/L | CO2 <18 mEq/L | | Thiazide diuretics | K down 0.3-0.7, Na down 2-5, glucose up 3-5 | K >3.5, Na >135 | K <3.5, Na <130 | | ACE inhibitors/ARBs | K up 0.3-0.5, creatinine up 10-15% | Creatinine rise stabilizes by wk 4 | K >5.5, creatinine rise >30% | | GH peptides | Glucose up 5-12 mg/dL | Glucose <100 fasting | Glucose >110 fasting repeatedly |

As the American Diabetes Association 2024 Standards of Care states: "Pharmacologic therapy should be adjusted based on serial laboratory assessment, not single time-point values, to distinguish drug effect from disease progression." Full text at diabetesjournals.org.

Optimal CMP Ranges vs. Standard Reference Ranges

Standard reference ranges are designed to minimize false positives in a population screening context. Optimal ranges for proactive health management are narrower and, in several cases, sex-specific.

Glucose

• Standard normal: 70-99 mg/dL fasting
• Optimal: 70-90 mg/dL fasting
• Prediabetes begins at 100 mg/dL; the average American at diagnosis of type 2 diabetes has had impaired fasting glucose for 5-10 years

Liver Enzymes

• ALT optimal (men): <25 U/L
• ALT optimal (women): <19 U/L
• AST should track ALT; AST/ALT ratio above 2:1 shifts suspicion toward alcohol-related liver disease or cirrhosis per AASLD guidance

Kidney Markers

• eGFR optimal: >90 mL/min/1.73m² for adults under 60; gradual physiologic decline of 1 mL/min/year after age 40 is expected
• BUN optimal: 10-18 mg/dL; values above 20 with normal creatinine suggest dehydration or high protein intake before kidney dysfunction
• BUN/creatinine ratio: 10:1-18:1 is optimal; above 20:1 suggests prerenal cause or catabolic state

Electrolytes

The Endocrine Society notes that serum sodium of 138-142 mEq/L and potassium of 4.0-4.5 mEq/L represent physiologically optimal ranges rather than the wider reference intervals printed on lab reports. The Endocrine Society clinical practice guidelines are indexed at endocrine.org.

Albumin above 4.5 g/dL correlates with better long-term outcomes in multiple longevity cohort analyses; values between 3.5-4.0 g/dL fall within "normal" but may indicate chronic inflammation, poor protein intake, or hepatic dysfunction. A 2015 meta-analysis in PLOS ONE (N=131,705) found that each 10 g/L decrease in albumin below 45 g/L was associated with a 137% increase in all-cause mortality risk.

When to Recheck and When to Act

Monitoring frequency depends on the drug, the baseline, and the direction of change.

Routine Monitoring Schedule

• Initiating GLP-1 agonist: CMP at baseline, 8-12 weeks, and 6 months, then annually if stable
• Initiating or adjusting TRT: CMP at baseline, 6 weeks, and 6 months; creatinine and ALT are the primary targets
• Initiating metformin: CMP at baseline, annually; sooner if clinical signs of renal compromise
• Starting thiazide diuretics: Electrolytes at baseline and 2-4 weeks; potassium and sodium are the targets
• Adding ACE inhibitor or ARB: Creatinine and potassium at 7-14 days after each dose change

Values That Require Same-Day Contact

Any of the following on a CMP result from a patient on hormone or metabolic therapy requires same-day clinical outreach, not a scheduled follow-up:

• Potassium <3.0 or >6.0 mEq/L
• Sodium <125 or >155 mEq/L
• CO2 <15 mEq/L (possible lactic acidosis or severe acidemia)
• Creatinine rise >50% from personal baseline within 4 weeks
• ALT >5x the upper limit of normal (above 150-200 U/L depending on the lab)
• Glucose >400 mg/dL fasting (hyperosmolar risk)

The CDC's chronic kidney disease surveillance data show that 37 million U.S. Adults have CKD, and 90% are unaware of their diagnosis before a lab abnormality is detected. CDC CKD data are available at cdc.gov. A CMP drawn as part of routine hormone therapy monitoring is often the first point of detection.